Streetbeat News

ENTA

Enanta Pharmaceuticals, Inc.

https://www.enanta.com

Industry

Biotechnology

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Open

6.87

Mkt cap

142M

Volume

341K

High

7.03

P/E Ratio

-1.34

52-wk high

17.80

Low

6.64

Div yield

N/A

52-wk low

4.71

Enanta Pharmaceuticals announced that its Phase 2A study of EDP-323 in healthy adults infected with RSV met primary and secondary endpoints, showing significant reductions in viral load and symptoms compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 10:02 am

JP Morgan analyst Eric Joseph maintains an Underweight rating on Enanta Pharma (NASDAQ:ENTA) and lowers the price target from $11 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:18 pm

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Enanta Pharma (NASDAQ:ENTA) and maintained a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:39 am

Enanta Pharma (NASDAQ:ENTA) reported Q3 2024 adjusted EPS of $(1.07), beating the $(1.45) estimate. Sales were $18.00M, surpassing the $17.18M estimate but down 4.72% from last year's $18.89M.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 8:18 pm

HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Enanta Pharma (NASDAQ:ENTA) but lowers the price target from $28 to $27.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 5:47 pm

JMP Securities analyst Roy Buchanan maintains a Market Outperform rating on Enanta Pharma (NASDAQ:ENTA) but lowers the price target from $23 to $22.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 3:34 pm

Enanta Pharma (NASDAQ:ENTA) reported Q2 2024 earnings with a GAAP EPS of $(1.47), missing the $(1.33) estimate by 10.53%, and sales of $17.054M, beating the $16.522M estimate by 3.22%. This represents a 17.88% improvement in EPS and a 4.16% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 8:05 pm

JP Morgan analyst Eric Joseph has maintained an Underweight rating on Enanta Pharma (NASDAQ: ENTA) and lowered the price target from $12 to $11.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 9:43 pm

Enanta Pharma (NASDAQ:ENTA) reported Q1 earnings with an EPS of $-1.58, missing estimates by 32.77% against an expected $-1.19. Revenue decreased by $5.58 million from the previous year. Despite a positive performance in the last quarter leading to an 11.52% share price increase, this quarter's results fell short of expectations.

Portfolio Pulse from Benzinga Insights

February 07, 2024 | 9:15 pm

Enanta Pharma (NASDAQ:ENTA) reported Q1 2024 earnings with a GAAP EPS of $(1.58), missing the $(1.23) estimate, and sales of $18.00M, missing the $21.95M estimate. This represents a decrease in both earnings and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 07, 2024 | 9:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.